Copertina

Assessing Post‐Marketing Requirements for Orphan Drugs: A Cross‐Sectional Analysis of FDA and EMA Oversight

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Jae Hyeon Yu, Sangwon Lee, Yoon Jung Kim, Won Young Kim, Min Jung Lee, Yun Kim
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Clinical Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Analysis of Real‐World Data Utilization in the Orphan Drug Approval Process: Focusing on New Drug Marketing Applications Submitted to the FDA
di: Minji Kim, et al.
Pubblicazione: (2026)

Country Contribution to Investigators of Pivotal Clinical Trials and Their Primary Publications of New Drugs Approved by the US Food and Drug Administration, 2012–2021
di: Yoona Choi, et al.
Pubblicazione: (2025)

Impact of Regulatory Post‐Market Safety Advisories on Prescribing Practices: An Interrupted Time Series Analysis
di: Seonji Kim, et al.
Pubblicazione: (2025)

Agreement about Availability of Alternative Treatments for Innovative Drugs Assessed by the EMA and HTA Organizations
di: Jorge Madrid Paredes, et al.
Pubblicazione: (2024)

Biomarker Utilization for Regulatory Decision Making: A Landscape Analysis of Neurological Drug Products Approved by FDA (2008–2024)
di: Dahee Jung, et al.
Pubblicazione: (2025)

Prognostic Implication of CYP2C19 Genotype According to Clinical Risk Stratification After Drug‐Eluting Stent Implantation
di: Hyun Woong Park, et al.
Pubblicazione: (2025)

Association of Influenza Vaccination During Pregnancy with Health Outcomes in Mothers and Children: A Population‐Based Cohort Study
di: Hyesung Lee, et al.
Pubblicazione: (2025)

Selected Acute Safety Events Following the Use of Nirmatrelvir/Ritonavir or Molnupiravir for COVID‐19: A Nationwide Cohort Study in South Korea
di: Ju Hwan Kim, et al.
Pubblicazione: (2024)

Orphan Designation for Drugs Approved in the United States and European Union: A Comparative Analysis
di: Enrico Costa, et al.
Pubblicazione: (2026)

Comprehensive Evaluation of OATP‐ and BCRP‐Mediated Drug–Drug Interactions of Methotrexate Using Physiologically‐Based Pharmacokinetic Modeling
di: Sejung Hwang, et al.
Pubblicazione: (2024)

Dose Determinations at Drug Approval Reviews: FDA‐Approved Drugs in Past 5 Years
di: Sachiko Mita, et al.
Pubblicazione: (2025)

Balancing Reassurance and Vigilance: Real‐World Evidence in Post‐Marketing Drug Safety
di: Yow‐Ming C. Wang, et al.
Pubblicazione: (2026)

Confirmatory Evidence Used in Non‐Oncologic Rare Disease New Molecular Entity Marketing Applications Approved by FDA, 2020–2023
di: Bridget M. Nugent, et al.
Pubblicazione: (2025)

Considerations for Industry—Preparing for the FDA Model‐Informed Drug Development (MIDD) Paired Meeting Program
di: Gerald R. Galluppi, et al.
Pubblicazione: (2024)

Current Status and Future Directions in the Development of Digital Therapeutic Interventions for Neurodevelopmental Disorders
di: Hyun‐ju Lee, et al.
Pubblicazione: (2025)

Use of FDA Expedited Programs and Development Timelines for New Molecular Entity Drug and New Biologic Approvals by Sponsor Experience
di: Kanhai S. Amin, et al.
Pubblicazione: (2025)

Uncovering Coenzyme Q10 ‐Related Genetic Determinants of Statin‐Associated Muscle Symptoms: Evidence from the UK Biobank and the All of Us Research Program
di: Da Hoon Lee, et al.
Pubblicazione: (2026)

Drug‐Induced Acute Pancreatitis: A Real‐World Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database
di: Dongxuan Li, et al.
Pubblicazione: (2024)

Participants in the FDA's Biomarker Qualification Program
di: Mahnum Shahzad, et al.
Pubblicazione: (2025)

Current Use of Physiologically Based Pharmacokinetic modeling in New Medicinal Product Approvals at EMA
di: Polly Paul, et al.
Pubblicazione: (2025)

Dose Optimization in Oncology Drug Development: Risk Factors for Postmarketing Requirements and Commitments
di: Hiroe Kitagaki, et al.
Pubblicazione: (2025)

Epidemiological Characteristics, Target Distribution, and Clinical Value of Targeted Anticancer Drugs Approved in China: A Cross‐Sectional Study
di: Ting Zhu, et al.
Pubblicazione: (2026)

FDA Approval Summary: Nalmefene Nasal Spray for the Emergency Treatment of Known or Suspected Opioid Overdose
di: Srikanth C. Nallani, et al.
Pubblicazione: (2024)

Impact of CYP2C19 Phenotype on Escitalopram Response in Geriatrics: Based on Physiologically‐Based Pharmacokinetic Modeling and Clinical Observation
di: Yoo Jin Jang, et al.
Pubblicazione: (2024)

Reply to: “Current Use of PBPK Modeling in New Medicinal Product Approvals at EMA: A Clinical Appraisal of Voclosporin in Lupus Nephritis”
di: Polly Paul, et al.
Pubblicazione: (2025)

FDA Experience on CAR T Cell Pharmacokinetics/Pharmacodynamics and Model‐Based Assessments
di: Million A. Tegenge, et al.
Pubblicazione: (2025)

Value of Pharmacogenetic Testing Assessed with Real‐World Drug Utilization and Genotype Data
di: Kaisa Litonius, et al.
Pubblicazione: (2024)

Mechanistic Modeling of Spatial Heterogeneity of Drug Penetration and Exposure in the Human Central Nervous System and Brain Tumors
di: Jing Li, et al.
Pubblicazione: (2024)

Post‐Approval Pediatric Use of Drugs Granted Waivers from Pediatric Testing
di: Ian T.T. Liu, et al.
Pubblicazione: (2026)

FDA Adverse Event Reporting System Essentials: A Reflection on Study Conception
di: Emanuel Raschi, et al.
Pubblicazione: (2025)

Clinical Pharmacology Characterization of Bispecific T‐Cell Engagers: A Summary Based on FDA Approvals
di: Ting Wang, et al.
Pubblicazione: (2025)

Dapagliflozin Reduces Urinary Kidney Injury Biomarkers in Chronic Kidney Disease Irrespective of Albuminuria Level
di: Junghyun Cho, et al.
Pubblicazione: (2024)

A Comprehensive CYP2D6 Drug–Drug–Gene Interaction Network for Application in Precision Dosing and Drug Development
di: Simeon Rüdesheim, et al.
Pubblicazione: (2025)

Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in Oncology
di: KyoungSoo Lim, et al.
Pubblicazione: (2024)

Evolving Standards: Good Clinical Practice Insights from US FDA , MHRA UK , and Health Canada
di: Cheryl Grandinetti, et al.
Pubblicazione: (2025)

A Comparative Clinical Pharmacology Analysis of FDA‐Approved Targeted Covalent Inhibitors vs. Reversible Inhibitors in Oncology
di: Huy X. Ngo, et al.
Pubblicazione: (2024)

Challenges and Possible Strategies to Address Them in Rare Disease Drug Development: A Statistical Perspective
di: Jie Chen, et al.
Pubblicazione: (2025)

Solanidine Metabolites as Diet‐Derived Biomarkers of CYP2D6‐Mediated Tamoxifen Metabolism in Breast Cancer Patients
di: Samantha Medwid, et al.
Pubblicazione: (2024)

Clinical Benefit, Trials, and Regulatory Approval of Oncology Indications Under Multiple Expedited Programs for Drug Marketing in China, 2018–2024
di: Jie Zhang, et al.
Pubblicazione: (2025)

A Hybrid Design Incorporating External Data to Evaluate Dexamethasone Intracameral Drug Delivery Suspension for Post‐Cataract Surgery Inflammation
di: Yuanyuan Zhao, et al.
Pubblicazione: (2025)